Nanobody Target GCC and Uses in Chimeric Antigen Receptor Cell Therapy
AssigneesInnovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.
InventorsZhiyuan Cao, Wei Ding, Guiting Han, Yuzhe Peng, Lei Xiao, Zhao Wu, Le Tian
Life of this patent
Estimating the term…
Abstract
The present disclosure describes compositions and methods of treating solid tumors using chimeric antigen receptor (CAR) T cell (CAR-T) therapy and/or antibodies targeting uanylate Cyclase 2C (GCC. GUCY2C). The compositions include CAR comprising an extracellular domain that binds GCC. Further disclosed are methods of using modified T ceils expressing a CAR that binds GCC for treating different types of carters.
Claims17
An isolated polynucleotide encoding a chimeric antigen receptor (CAR) that binds to GCC, wherein the CAR comprises:
- an extracellular domain that binds to GCC;
- a transmembrane domain;
- and an intracellular domain, the extracellular domain comprising SEQ ID NO:
- 237, 472, 225, or 475.
Dependencies are inferred from the claim text.